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We do disagree with some of the statements made in
Graham and O’Kane’s letter regarding the issues surrounding
graft patency and myocardial infarction. That issue is
extremely complex and the subject of great international
debate. One should not conclude that aprotinin causes
myocardial infarction, a hypercoagulable state, or an inde-
pendent effect leading to a “bad outcome.” It is not our wish
to debate this point. However, a number of papers that pro-
vide an opposing view regarding these issues were not quoted
by Graham and O’Kane. 
In conclusion, the international debate regarding the effects
of aprotinin and antifibrinolytic agents on myocardial infarc-
tion and graft patency is separate from the data and conclu-
sions presented by our article. 
Bruce D. Spiess, MD
Professor and Chief
Cardiothoracic Anesthesia
Virginia Commonwealth University
Medical College of Virginia
Richmond, VA 23298
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Myocardial “hybrid” revascularization: Intermedi-
ate results of an alternative approach to multivessel
coronary artery disease
To the Editor:
Revascularization of multivessel coronary artery disease
with the left internal thoracic artery (LITA) and additional
vein grafts using cardiopulmonary bypass (CPB) and cardio-
plegic arrest currently represents the standard technique in
coronary surgery.1 Aiming for less invasive cardiac surgery,
several groups have reported encouraging results with mini-
mally invasive direct coronary artery bypass (MIDCAB)
grafting of the left anterior descending coronary artery (LAD)
to anterior cardiac vessels on a beating heart without CPB
through a left anterolateral minithoracotomy.2,3 However, due
to limited access through the small incision, this approach
cannot be applied to multivessel revascularization without
additional incisions or use of CPB. So that the benefits of
MIDCAB approaches could be extended to patients with
multivessel disease, a safe and effective integrated coronary
revascularization procedure combining minimally invasive
surgical revascularization of the LAD with interventional
procedures was introduced.4,5 Very promising results in a
series of 31 patients were recently published by Zenati and
associates.6 Having reported similar initial results in 35 con-
secutive patients undergoing this integrated “hybrid” proce-
dure in a multicenter experience,7 we present here subsequent
intermediate follow-up results in 26 patients who underwent
hybrid revascularization in Hannover, Germany.
Between December 1996 and January 1999, 21 men and 5
women (mean age 56.6 ± 18.8 years) underwent a hybrid
revascularization performed as a primary MIDCAB proce-
dure for grafting of the LAD to the LITA followed by staged
angioplasty (n = 23) and stenting (n = 8) of additional coro-
nary lesions. Five patients had a moderately reduced left ven-
tricular ejection fraction between 30% and 50% and 3
patients had a left ventricular ejection fraction of less than
30%. The distribution pattern of 1-, 2-, and 3-vessel disease
was 4, 14, and 8, respectively. Previous myocardial infarc-
tions were recorded in 16 patients. The degree of revascular-
ization achieved during the operation was “anatomically
complete” in 18 patients (69.2%) and “anatomically incom-
plete but functionally adequate” in 8 patients (30.8%). After
an uneventful postoperative course, coronary re-angiography
at the time of intervention revealed patent and functioning
LITA grafts in all patients. Procedure-related complications
did not occur. All patients remained angina-free and had
stress electrocardiograms showing no abnormalities within
30 days after the operation. 
At a mean interval of 11.4 ± 7.7 months after the operation,
all patients are alive. Follow-up information was obtained at
the time of follow-up coronary angiography in 15 patients.
The remaining 11 patients refused the angiographic examina-
tion because of complete absence of any symptoms but were
contacted by telephone.
Two patients with angina on moderate exertion required
additional interventions because of new significant lesions in
other than the previously revascularized coronary arteries.
One patient was completely free of symptoms with a subtotal
restenosis in the formerly dilated right coronary artery and
was maintained on medical therapy alone. All other patients
were angina-free without signs of acute ischemia on stress
electrocardiogram. Angiographically, LITA anastomoses and
interventionally treated coronary arteries were found to be
patent. None of the patients had had any ischemic coronary
events after the hybrid procedure.
Thus we can confirm the excellent result described by
Zenati and associates6 after integrated coronary revasculariza-
tion. In our experience, the hybrid approach of myocardial
revascularization by means of a LITA-LAD MIDCAB proce-
dure followed by additional interventional therapy appears to
be safe and effective in complete or near-complete coronary
revascularization in patients with multivessel disease.
Subgroups of patients who might receive special benefit from
this new approach include the very elderly and patients requir-
ing reoperation with significant comorbidity and a high-risk
constellation for CPB with median sternotomy. Also, younger
and otherwise healthy patients with aggressive 2-vessel dis-
ease, in whom further coronary revascularization procedures
seem likely, may benefit from this hybrid approach rather than
a less invasive procedure using the Octopus system
(Medtronic, Inc, Minneapolis, Minn).8,9 Although the latter
procedure eliminates the potential adverse effects associated
with CPB, it still requires a median sternotomy and manipula-
tion of the aorta with a potentially high risk of neurologic
damage in case of calcifications. Furthermore, one of the main
limitations to the approach with the Octopus tissue stabilizer
is the difficult accessibility of target vessels in the circumflex
system,8 whereas these regions are suitable for hybrid percu-
taneous transluminal angioplasty in most cases.
As progressively more centers achieve excellent experience
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with this integrated approach,10 detailed evaluation in larger
randomized multicenter studies is warranted to document
long-term effectiveness of hybrid revascularization compared
with conventional coronary artery bypass grafting or inter-
ventional therapy alone.
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Mechanical mitral valves without long-term antico-
agulation up to thirteen years
To the Editor:
If a mechanical valve could be left without anticoagulation,
a continuous risk factor for severe bleeding, with an inci-
dence of around 1% every year, could be avoided.
Ordinary Björk-Shiley Monostrut heart valves (Shiley, Inc,
Irvine, Calif) were inserted in the mitral position in goats.
After 1 year without anticoagulation, we found no instances
of thrombosis on the pyrolytic discs or on the metal struts, but
the suture rings in all cases were covered by an endothelial-
ized layer of thrombus. From this layer a thrombus did pro-
trude into the valve orifice in 8 of 9 goats.
The solution was to catch the covering from the suture ring
and have it endothelialized and firmly fixed to the metal ring.1
It was possible to sinter small, 20 to 30 m m round pearls of the
same metal to the metal ring of the valves at high temperature
in 3 layers. This enables roots to develop between the pearls
so that the covering will not come loose. An endothelialized
covering always developed on microporous surfaced rings tied
into the superior vena cava in goats.2 With 100 m m pearls the
vascular covering was too thick.2
In 1984 we started to implant the microporous surfaced
mitral valve in goats. After 21⁄2 months without anticoagulation,
the microporous area showed a homogeneous endothelialized
surface with nutrition direct from the blood so that it stayed
thin for more than 5 years.3 The continuous covering from the
suture ring went over the groove down in the valve, and after 5
years without anticoagulation the valve was still nicely covered
and the goats produced offspring without problems.3
The pilot study. This microporous surfaced mitral valve
prosthesis has the same strength as the Björk-Shiley
Monostrut valve,4 which has been implanted in about 140,000
patients during a 17-year period without any mechanical fail-
ures. We operated on a small group of 12 patients 11 and 13
years ago.5 All these patients had sinus rhythm. There were 5
children aged 7 to 15 years with mitral insufficiency and car-
diomegaly.5 Patient 10 was cachectic and needed enteral nutri-
tion for weeks before the operation. An 8-year-old boy (case
9) had a severe form of sickle cell anemia, with a hemoglobin
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Fig 1. The microporous surfaced 25 mm mitral Björk-Shiley
Monostrut heart valve after 21⁄2 years without anticoagulation in
a goat. The valve is viewed from the left ventricle with the disc
in the open position. The carbon-coated Teflon suture ring is
covered with thin, smooth, glistening yellow endothelium
extending over the groove and adjacent part of the valve flange.
